7+3 (cytarabine + anthracycline) ± midostaurin
Checked 2026-09-09
Fit adults with newly diagnosed AML; midostaurin for FLT3-mutated disease (quizartinib for FLT3-ITD)
One cycle
every 28 days × 1-2 · about 4 weeks in totalComponents
| Drug | Dose | Route | Days | Note |
|---|---|---|---|---|
Cytarabine | 100-200 mg/m² per day | IV | D1-7 (168 h infusion) | |
Daunorubicin 60-90 mg/m² or idarubicin 12 mg/m² | daily | IV | D1-3 | |
Midostaurin (FLT3-mutated) Small-molecule multikinase inhibitor (FLT3) | 50 mg twice daily | Oral | D8-21 |
Cycles
1-2 induction, then consolidation
28-day cycle
Emetogenicity
Moderate (30-90%)
G-CSF
Not routine
Notes
- Gemtuzumab ozogamicin 3 mg/m² on days 1, 4 and 7 is added for favourable-risk CD33-positive AML (ALFA-0701).
Used in
Source
RATIFY, NEJM 2017; NCCN Acute Myeloid Leukemia
Reference doses for a typical adult from the cited protocol or label. Doses are adjusted for renal and hepatic function, age, performance status and prior toxicity, and institutional protocols vary. Verify against the current label and your local protocol before treating. Not medical advice.